IX BIOPHARMA LTD. — Proxy Solicitation & Information Statement 2026

Apr 23, 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING

==> picture [190 x 74] intentionally omitted <==

IX BIOPHARMA LTD.

(Incorporated in the Republic of Singapore on 8 May 2004) (Company Registration No. 200405621W)

Unless otherwise defined, all capitalised terms used herein shall bear the same meaning as used in the circular dated 23 April 2026 issued by iX Biopharma Ltd. (the " Circular ").

NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting of iX Biopharma Ltd. (" Company ") will be held at 2 Science Park Drive, Ascent Main Lobby, The Metro, Singapore 118222 on Friday, 8 May 2026 at 10:00 a.m. for the purpose of considering and, if thought fit, passing with or without modifications, the following Ordinary Resolutions:

ORDINARY RESOLUTION

1) PROPOSED ALLOTMENT AND ISSUANCE OF 1,045,164 SHARES TO ANSON PROPERTIES PTE. LTD.

(Resolution 1)

That:

• (a) approval be given for the proposed allotment and issuance of 1,045,164 Subscription Shares to Anson Properties Pte. Ltd. pursuant to the Anson Placement; and

• (b) the Directors be authorised to do all such acts and things (including without limitation, entering into all such transactions, arrangements and agreements and executing all such documents) as they may consider necessary or expedient for the purposes of giving effect to this Ordinary Resolution.

2) PROPOSED ALLOTMENT AND ISSUANCE OF 106,168 SHARES TO MR. PATRICK DONALD DAVIES

(Resolution 2)

That:

• (a) approval be given for the proposed allotment and issuance of 106,168 Directors’ Shares to Mr. Patrick Donald Davies pursuant to the Directors’ Placement; and

• (b) the Directors (save for Mr. Patrick Donald Davies) be authorised to do all such acts and things (including without limitation, entering into all such transactions, arrangements and agreements and executing all such documents) as they may consider necessary or expedient for the purposes of giving effect to this Ordinary Resolution.

N-1

NOTICE OF EXTRAORDINARY GENERAL MEETING

3) PROPOSED ALLOTMENT AND ISSUANCE OF 99,051 SHARES TO MR. (Resolution 3) TEO WOON KENG JOHN

That:

• (a) approval be given for the proposed allotment and issuance of 99,051 Directors’ Shares to Mr. Teo Woon Keng John pursuant to the Directors’ Placement; and

• (b) the Directors (save for Mr. Teo Woon Keng John) be authorised to do all such acts and things (including without limitation, entering into all such transactions, arrangements and agreements and executing all such documents) as they may consider necessary or expedient for the purposes of giving effect to this Ordinary Resolution.

4) PROPOSED ALLOTMENT AND ISSUANCE OF 99,051 SHARES TO MR. (Resolution 4) ALBERT HO SHING TUNG

That:

• (a) approval be given for the proposed allotment and issuance of 99,051 Directors’ Shares to Mr. Albert Ho Shing Tung pursuant to the Directors’ Placement; and

• (b) the Directors (save for Mr. Albert Ho Shing Tung) be authorised to do all such acts and things (including without limitation, entering into all such transactions, arrangements and agreements and executing all such documents) as they may consider necessary or expedient for the purposes of giving effect to this Ordinary Resolution.

5) PROPOSED GRANT OF SHARE AWARDS TO MR. EDDY LEE YIP HANG (Resolution 5) PURSUANT TO THE iX PERFORMANCE SHARE PLAN

That:

• (a) approval be given for the proposed grant of an Award of an aggregate of 3,036,996 Award Shares to Mr. Eddy Lee Yip Hang pursuant to and in accordance with the Rules of the iX Performance Share Plan (the “LYH Award”), on the terms and conditions set out in the Circular, including the vesting schedule comprising:

• (i) 1,012,332 Award Shares vesting on the date of approval;

• (ii) 1,012,332 Award Shares vesting on 28 February 2027; and (iii) 1,012,332 Award Shares vesting on 29 February 2028; and

• (b) the Directors (save for Mr. Eddy Lee Yip Hang) be authorised to allot and issue and/or transfer from time to time such number of Shares as may be required to satisfy the vesting and release of the LYH Award in accordance with the Rules of the iX Performance Share Plan, and to do all such acts and things (including without limitation, entering into all such transactions, arrangements and agreements and executing all such documents) as they may consider necessary or expedient for the purposes of giving effect to this Ordinary Resolution.

By Order of the Board

Eddy Lee Yip Hang Chairman and CEO

23 April 2026 Singapore

N-2

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTES:

• (1) The Company’s Notice of EGM, Circular dated 23 April 2026 and the accompanying proxy form (“ Proxy Form ”) will be published on the Company’s website at https://www.ixbiopharma.com/newsroom/ or the SGX website at https://www.sgx.com/securities/companyannouncements. Printed copies of this Notice of EGM and the accompanying Proxy Form will be sent to members by post.

Printed copies of the Circular will not be sent to members. A member may request for a printed copy of the Circular at the Company’s principal place of business during office hours (Monday - Friday, 9.00 a.m - 5.30 p.m.), at 1 Kim Seng Promenade #14-01 Great World City East Lobby Singapore 237994 no later than 5.30 p.m. on 30 April 2026.

• (2) Members (whether corporate or individual) may vote in person at the EGM or appoint a proxy, including the Chairman of the EGM, to attend, speak and vote on his/her/its behalf at the EGM. If appointing a proxy or proxies, members must give specific instructions as to his manner of voting, or abstentions from voting, in the Proxy Form. Where no specific voting direction is given to the proxy/proxies, the proxy/proxies will vote or abstain from voting at his/her/their discretion, on any matter arising at the EGM and at any adjournment thereof. Only members of the Company or their appointed proxy(ies) whose identities have been duly verified will be entitled to attend the EGM.

(3) A member who is not a Relevant Intermediary is entitled to appoint up to two (2) proxies to attend, speak and vote at the EGM. Where such member appoints two (2) proxies, he/she should specify the proportion of his/her shareholding (expressed as a percentage of the whole) to be presented by each proxy in the Proxy Form. If no such proportion or number is specified, the first named proxy shall be deemed to represent 100% of his/her shareholding and the second named proxy shall be deemed to be an alternate to the first named.

“Relevant Intermediary” has the meaning ascribed to it in Section 181 of the Companies Act 1967.

A member who is a Relevant Intermediary is entitled to appoint more than two (2) proxies to attend, speak and vote at the EGM, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member appoints more than two (2) proxies, the number of shares in relation to which each proxy has been appointed shall be specified in the Proxy Form. A proxy need not be a member of the Company.

(4) The Proxy Form must be under the hand of the appointor or by his/her attorney duly authorised in writing. Where the Proxy Form is executed by a corporation, it must be executed as a deed in accordance with the Companies Act or under the hand of an attorney or an officer duly authorised, or in some other manner approved by the directors. Where the Proxy Form is executed by an attorney on behalf of the appointer, the letter or power of attorney or a duly certified copy thereof must be lodged at the Company’s Share Registrar, Tricor Barbinder Share Registration Services, at 9 Raffles Place, #26-01 Republic Plaza Tower I, Singapore 048619.

(5) The Proxy Form must be submitted to the Company in the following manner:

(a) if submitted personally or by post, be lodged with the Company’s Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place, #26-01 Republic Plaza Tower I, Singapore 048619; or

(b) if submitted electronically, be submitted via email to the Company at agm@ixbiopharma.com, and in each case, must be lodged and received (as the case may be) not less than seventy-two (72) hours before the time appointed for the EGM (i.e. by 10.00 a.m. on 5 May 2026).

(6) An investor who buys shares using CPF monies and/or SRS monies (“ CPF and SRS Investor ”) (as may be applicable) may attend and cast his/her vote(s) at the EGM in person. CPF and SRS Investors who are unable to attend the EGM but would like to vote, may inform their CPF and/or SRS Approved Nominees (CPF agent banks or SRS operators) to appoint the Chairman of the EGM to act as their proxy, in which case, the CPF and SRS Investors shall be precluded from attending the EGM.

(7) CPF and SRS Investors who wish to exercise their voting rights at the EGM should approach the CPF Agent bank or SRS operators (as the case may be) to submit their votes at least seven (7) working days before the EGM (i.e. by 5.00 p.m. on 28 April 2026) in order to allow sufficient time for their respective relevant intermediaries to submit the Proxy Form to vote on their behalf by the cut-off date. CPF and SRS Investors should not directly appoint the Chairman of the EGM as proxy to direct the vote.

Submission of questions prior to the EGM

(8) All questions from members may be submitted in advance of the EGM, by 5.30 p.m. on 29 April 2026, either (a) in hard copy by sending personally or by post at the Company’s principal place of business at 1 Kim Seng Promenade, #14-01, Great World City East Lobby, Singapore 237994; (b) or electronically, via email to the Company at agm@ixbiopharma.com.

Members submitting questions are required to provide their particulars as follows: (a) Full name (for individuals) or company name (for corporates) as per CDP/SRS account records;

(b) National Registration Identity Card Number or Passport Number (for individuals) / Company Registration Number (for corporates);

(c) Number of shares held, in the capital of the Company; (d) Contact Number; and

(e) Email Address.

(9) Members are strongly encouraged to submit questions and Proxy Forms electronically, via email.

(10) The Management and Board of Directors of the Company will endeavour to address all substantial and relevant questions received from members by 10:00 a.m. on 3 May 2026 (i.e. 48 hours prior to the closing date and time for the lodgement of the proxy forms). The Company’s responses to questions raised by members shall be published on the Company’s website at https://www.ixbiopharma.com/newsroom/ or the SGX website at https://www.sgx.com/securities/company-announcements.

PERSONAL DATA PRIVACY:

By submitting a Proxy Form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the EGM and/or any adjournment thereof, a member of the Company consents to the collection, use and disclosure of the member’s personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of proxies and representatives appointed for the EGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the EGM (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines.

N-3